Abstract / Summary
Abstract Medications for opioid use disorder (MOUD) reduce overdose mortality, yet most individuals with opioid use disorder receive no pharmacotherapy. Facility-level health information technology may reflect broader organizational capacity, but it has rarely been examined as a marker associated with readiness to offer evidence-based opioid care. This cross-sectional secondary analysis of the 2024 National Substance Use and Mental Health Services Survey (N-SUMHSS) Public Use File included a base sample of 20,813 substance use disorder treatment facilities and used complete-case adjusted logistic regression to examine whether exclusive electronic health record (EHR) use, defined as reliance on an EHR with no paper charts, was associated with the availability of buprenorphine, naltrexone, take-home naloxone with overdose education, and co-occurring opioid use disorder services. Models adjusted for ownership, program focus, opioid treatment program (OTP) registration, and financial access characteristics; federally regulated OTP methadone availability served as a regulatory contrast. Among facilities with valid EHR responses ( n = 16,107), 68.3% reported exclusive EHR use. Exclusive EHR use was associated with higher adjusted odds of buprenorphine (aOR = 3.05), naltrexone (aOR = 2.90), take-home naloxone with overdose education (aOR = 3.18), and co-occurring services (aOR = 2.33), and more weakly with federally regulated OTP methadone availability (aOR = 1.23). Exclusive EHR use is an organizational marker associated with service availability, but the cross-sectional design and potential residual confounding preclude causal conclusions about whether EHR investment would expand opioid treatment access.